


Extended Data Table 1: Post-2021 Independent Benchmark Genes

63 genes from publications post-dating L2G training cutoff (2021) · Verified absent from all training sets



a

b

Tier1_Mendelian · 35 genes

ClinGen Definitive evidence · (Mendelian disease causative)

LDLR	APOB	APOE
BRCA1	TP53	CFTR
GCK	HNF1A	KCNJ11
MC4R	HBB	HBA1
DMD	PKD1	UMOD
APC	SNCA	LRRK2
GBA	MYBPC3	SERPINA1
F8	FMR1	HFE
LEP	LRP5	COL1A1
GJB2	SLC26A4	MYOC
ABCA4	HEXA	HLA-DRB1
TSHR	TG	

c

Tier1_Coding · 14 genes

Functional coding variants · (protein-altering mutations)

LPA	SLC30A8
CAD/Lp(a) levels	T2D protection (LoF)
APOC3	NOD2
Triglycerides/CAD	Crohn's disease
PTPN22	TYK2
RA/T1D R620W	SLE/MS P1104A
APOL1	SLC2A9
CKD G1/G2 variants	Uric acid/gout
PNPLA3	TM6SF2
NAFLD I148M	NAFLD E167K
CFH	TREM2
AMD Y402H	AD R47H
SORL1	IRS1
AD trafficking	T2D insulin resistance

d


Tier1_CRISPR · 7 genes

CRISPR/perturbation validated · (functional screen evidence)

PCSK9	ANGPTL3	IRX3
LDL/CAD drug target	LDL/TG evinacumab	Obesity FTO target
CHD8	WNT16	MTNR1B
Autism chromatin	Bone density Wnt	Glucose/circadian

Disease Categories · 17 areas covered

Comprehensive coverage across human disease



Tier1_Drug · 6 genes

FDA-approved targets · (2021-2024 approvals)

IL23R	PPARG	JAK2
IBD anti-IL23	T2D thiazolidinediones	MPN JAK inhibitors
CETP	CACNA1C	Psych Ca channel

Source: data/processed/baselines/post2021_independent_benchmark_FINAL.tsv